CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

NP-120 (Ifenprodil)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug498 CT-V Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

The purpose of this adaptive trial is to determine the clinical efficacy of Ifenprodil in the treatment of patients infected with COVID-19. This Protocol is largely based on the recommendations of the WHO R&D Blueprint Clinical Trials Expert Group COVID-19 Therapeutic Trial Synopsis, and associated Master Protocol. The choice of the primary outcome measure will be determined by a pilot study of the first 150 subjects. Subject clinical status (on a 7-point ordinal scale) at day 15 in treatment versus the control group is the default primary endpoint.

NCT04382924 COVID Drug: NP-120 (Ifenprodil)

Primary Outcomes

Description: Not hospitalized, no limitations on activities Not hospitalized, limitation on activities Hospitalized, not requiring supplemental oxygen Hospitalized, requiring supplemental oxygen Hospitalized, on non-invasive ventilation or high flow oxygen devices Hospitalized, on invasive mechanical ventilation or ECMO Death

Measure: Patient clinical status (on the WHO 7-point ordinal scale) at day 15 in IP versus SOC control group patients:

Time: Day 15

Secondary Outcomes

Measure: Status on an ordinal scale assessed daily while hospitalized and on days 15 and 28 in IP versus control group patients

Time: Days 1 through 28

Measure: NEWS assessed days 3, 5, 8 ,11 daily while hospitalized and on days 15 and 29 in IP versus control group patients

Time: Days 3, 5, 8, 11, 25, 29

Measure: Rate of mechanical ventilation in IP versus control group patients

Time: Day 15, 28

Measure: Duration of mechanical ventilation (if applicable) in IP versus control group patients

Time: Day 15, 28

Measure: Duration of supplemental oxygen in IP versus control group patients

Time: Day 15, 28

Measure: Time to return to room pressure (SpO2 > 94%) on room air

Time: Day 15, 28

Measure: Duration in ICU (if applicable) in IP versus control group patients

Time: Day 15, 28

Measure: Rate of Mortality in IP versus control group patients

Time: Day 15, 28

Measure: Duration of hospitalization in IP versus control group patients

Time: Day 15, 28

Measure: Time to discharge in IP versus control group patients

Time: Day 15, 28

Measure: Effect on the rate of change of partial pressure of oxygen (PaO2) and PaO2/FiO2 ratio taken at baseline and measured once daily up to 2 weeks of treatment in IP versus control group patients

Time: Up to day 15, day 28

No related HPO nodes (Using clinical trials)